Activated FGFR2 mutants bind FRS2

Stable Identifier
R-HSA-5655339
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

After activation, FGFR mutants are presumed to recruit FRS2 (also known as FRS2alpha). This has been demonstrated in some cases (see for instance Ahmed, 2008; Weiss, 2010; Dutt, 2008; Dutt, 2011; Cha, 2009; Qing, 2009; Bai, 2010 ) and is inferred to occur in others by analogy with the wild-type receptor.

Literature References
PubMed ID Title Journal Year
19103595 Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform

Cha, JY, Maddileti, S, Mitin, N, Harden, TK, Der, CJ

J Biol Chem 2009
18373495 Extracellular point mutations in FGFR2 elicit unexpected changes in intracellular signalling

Ahmed, Z, Schüller, AC, Suhling, K, Tregidgo, C, Ladbury, JE

Biochem J 2008
19381019 Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

Qing, J, Du, X, Chen, Y, Chan, P, Li, H, Wu, P, Marsters, S, Stawicki, S, Tien, J, Totpal, K, Ross, S, Stinson, S, Dornan, D, French, D, Wang, QR, Stephan, JP, Wu, Y, Wiesmann, C, Ashkenazi, A

J Clin Invest 2009
18552176 Drug-sensitive FGFR2 mutations in endometrial carcinoma

Dutt, A, Salvesen, HB, Chen, TH, Ramos, AH, Onofrio, RC, Hatton, C, Nicoletti, R, Winckler, W, Grewal, R, Hanna, M, Wyhs, N, Ziaugra, L, Richter, DJ, Trovik, J, Engelsen, IB, Stefansson, IM, Fennell, T, Cibulskis, K, Zody, MC, Akslen, LA, Gabriel, S, Wong, KK, Sellers, WR, Meyerson, M, Greulich, H

Proc Natl Acad Sci U S A 2008
21160078 Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer

Weiss, J, Sos, ML, Seidel, D, Peifer, M, Zander, T, Heuckmann, JM, Ullrich, RT, Menon, R, Maier, S, Soltermann, A, Moch, H, Wagener, P, Fischer, F, Heynck, S, Koker, M, Schöttle, J, Leenders, F, Gabler, F, Dabow, I, Querings, S, Heukamp, LC, Balke-Want, H, Ansén, S, Rauh, D, Baessmann, I, Altmüller, J, Wainer, Z, Conron, M, Wright, G, Russell, P, Solomon, B, Brambilla, E, Brambilla, C, Lorimier, P, Sollberg, S, Brustugun, OT, Engel-Riedel, W, Ludwig, C, Petersen, I, Sänger, J, Clement, J, Groen, H, Timens, W, Sietsma, H, Thunnissen, E, Smit, E, Heideman, D, Cappuzzo, F, Ligorio, C, Damiani, S, Hallek, M, Beroukhim, R, Pao, W, Klebl, B, Baumann, M, Buettner, R, Ernestus, K, Stoelben, E, Wolf, J, Nürnberg, P, Perner, S, Thomas, RK

Sci Transl Med 2010
20709759 GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling

Bai, A, Meetze, K, Vo, NY, Kollipara, S, Mazsa, EK, Winston, WM, Weiler, S, Poling, LL, Chen, T, Ismail, NS, Jiang, J, Lerner, L, Gyuris, J, Weng, Z

Cancer Res 2010
21666749 Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

Dutt, A, Ramos, AH, Hammerman, PS, Mermel, C, Cho, J, Sharifnia, T, Chande, A, Tanaka, KE, Stransky, N, Greulich, H, Gray, NS, Meyerson, M

PLoS One 2011
Participants
Participant Of
Normal reaction
Disease
Name Identifier Synonyms
bone development disease 0080006
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created